Company:Bharat Biotech

From HandWiki
Short description: Indian multinational biotechnology company and vaccine manufacturer

[ ⚑ ] 17°39′55″N 78°36′17″E / 17.6652°N 78.6047°E / 17.6652; 78.6047

Bharat Biotech International Limited
TypePrivate Limited Company
IndustryBiotechnology
Founded1996; 28 years ago (1996)
FounderKrishna Ella
HeadquartersGenome Valley, Turakapally, Hyderabad
Area served
Worldwide
Key people
Krishna Ella
(Chairman & MD)
Products
  • ROTAVAC,[1]
  • TypbarTCV,[2]
  • Biopolio
  • Comvac
  • JENVAC
  • COVAXIN
SubsidiariesChiron Behring Vaccines [3]
Websitewww.bharatbiotech.com

Bharat Biotech International Limited (BBIL) is an India biotechnology company headquartered in the city of Hyderabad, India engaged in the drug discovery, drug development, manufacture of vaccines, bio-therapeutics, pharmaceuticals and health care products.[4]

Overview

Bharat Biotech has its manufacturing facility situated at Genome Valley, Hyderabad, India.[4] As of July 2020, the company has over 700 employees[5] and has a presence worldwide.[4]

The company has been responsible for developing an eco-friendly recombinant[6] and a naturally attenuated strain derived Rotavirus vaccine called ROTAVAC.[7][8] They were one of the first to develop vaccines for viral diseases like Chikungunya[9][10] and Zika.[11][12] The company also produces vaccines for Japanese Encephalitis.[13] Bharat Biotech has biosafety level 3 (BSL3) laboratories.[14]

COVID-19 vaccine development

In April 2020, the company announced that they have partnered with US-based company FluGen and University of Wisconsin-Madison to develop a COVID-19 vaccine.[15][16]

A 5ml vial of Covaxin

In May 2020, Indian Council of Medical Research's (ICMR's) National Institute of Virology approved and provided the virus strains for developing a fully indigenous COVID-19 vaccine.[17][18] On June 29, 2020, the company got permission to conduct Phase 1 and Phase 2 clinical trials in India for a developmental COVID-19 vaccine named Covaxin, from the Drugs Controller General of India (DCGI), Government of India.[19][20][21][22] The Central Drugs Laboratory (CDL) at Kasauli in Himachal Pradesh has been engaged in testing experimental batches of Bharat Biotech's COVID-19 vaccine Covaxin on a priority basis.[23] A total of 12 sites were selected by the Indian Council for Medical Research for Phase I and II randomised, double-blind and placebo-controlled clinical trials of vaccine candidate.[24][25]

In September 2020, the company announced that it was going to manufacture the novel chimp-adenovirus, a single dose intranasal vaccine (codenamed BBV154) for COVID-19 being developed in collaboration with the American company Precision virologics[26] and Washington University School of Medicine in St. Louis, Missouri. It is currently undergoing clinical trials.[27][28] On October 12 2021, Bharat Biotech's Covaxin got approved for usage on children between 2 and 18 years of age. [29]

Attempted data theft

In March 2021, Reuters reported that Chinese state-backed cyber-espionage group Red Apollo targeted Bharat Biotech's intellectual property for exfiltration.[30]

See also

References

  1. ↑ "WHO prequalifies new rotavirus vaccine". https://www.who.int/medicines/news/2018/prequalified_new-rotavirus_vaccine/en/. 
  2. ↑ "WHO recommends use of first typhoid conjugate vaccine". https://www.who.int/immunization/newsroom/press/who_recommends_use_first_typhoid_conjugate_vaccine/en/. 
  3. ↑ "Bharat Biotech buys Chiron Behring Vaccines from GSK" (in en). 15 February 2019. https://www.thehindubusinessline.com/companies/bharat-biotech-buys-chiron-behring-vaccines-from-gsk/article26279438.ece. 
  4. ↑ 4.0 4.1 4.2 "Bharat Biotech International Ltd". https://www.bloomberg.com/profile/company/7535940Z:IN. 
  5. ↑ "Leading Biotech Vaccine Manufacturers in India - Bharat Biotech". https://www.bharatbiotech.com/overview.html. 
  6. ↑ "Process for the preparation and purification of recombinant proteins" (in en). US patent No US8956812B2. 23 August 2004. https://patents.google.com/patent/US8956812B2/en. 
  7. ↑ Bhandari, Nita; Rongsen-Chandola, Temsunaro; Bavdekar, Ashish; John, Jacob; Antony, Kalpana; Taneja, Sunita; Goyal, Nidhi; Kawade, Anand et al. (June 2014). "Efficacy of a monovalent human-bovine (116E) rotavirus vaccine in Indian infants: a randomised, double-blind, placebo-controlled trial". The Lancet 383 (9935): 2136–2143. doi:10.1016/S0140-6736(13)62630-6. PMID 24629994. 
  8. ↑ Kang, G (October 2006). "Rotavirus vaccines.". Indian Journal of Medical Microbiology 24 (4): 252–7. doi:10.1016/S0255-0857(21)02284-2. PMID 17185842. 
  9. ↑ "Bharat Biotech's Zika, Chikungunya vaccines to enter Phase II trials; focus now on private label market". Moneycontrol. https://www.moneycontrol.com/news/business/companies/bharat-biotechs-zika-chikungunya-vaccines-to-enter-phase-ii-trials-focus-now-on-private-label-market-3633391.html. 
  10. ↑ "CEPI, 치쿤구니아 백신 개발 위해 국제백신연구소-바라트 바이오텍 컨소시엄에 최대 1410만달러 지원" (in ko). CEPI, 치쿤구니아 백신 개발 위해 국제백신연구소-바라트 바이오텍 컨소시엄에 최대 1410만달러 지원 - 뉴스와이어. 3 June 2020. https://www.newswire.co.kr/newsRead.php?no=905832. 
  11. ↑ "Bharat Biotech gets breakthrough in developing Zika vaccine". The Economic Times. 4 February 2016. https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/bharat-biotech-gets-breakthrough-in-developing-zika-vaccine/articleshow/50835450.cms?from=mdr. 
  12. ↑ "CEPI awards up to US$14.1million to consortium of IVI and Bharat Biotech to advance development of Chikungunya vaccine in collaboration with Ind-CEPI – IVI". International Vaccine Institute. 3 June 2020. https://www.ivi.int/cepi-awards-up-to-us14-1million-to-consortium-of-ivi-and-bharat-biotech-to-advance-development-of-chikungunya-vaccine-in-collaboration-with-ind-cepi/. 
  13. ↑ Singh, Anit; Mitra, Monjori; Sampath, Gadey; Venugopal, P.; Rao, J. Venkateswara; Krishnamurthy, B.; Gupta, Mukesh Kumar; Sri Krishna, S. et al. (1 September 2015). "A Japanese Encephalitis Vaccine From India Induces Durable and Cross-protective Immunity Against Temporally and Spatially Wide-ranging Global Field Strains". Journal of Infectious Diseases 212 (5): 715–725. doi:10.1093/infdis/jiv023. PMID 25601942. 
  14. ↑ "Slow off the starting blocks for Bharat Biotech's Covaxin mass production". 17 May 2021. https://www.newindianexpress.com/nation/2021/may/17/slow-off-the-starting-blocks-for-bharat-biotechscovaxin-mass-production-2303416.html. 
  15. ↑ "UW-Madison, Flugen, Bharat Biotech to develop coroflu, a coronavirus vaccine". https://ghi.wisc.edu/uw-madison-flugen-bharat-biotech-to-develop-coroflu-a-coronavirus-vaccine/. 
  16. ↑ "Bharat Biotech ties up with US varsity for Covid vaccine" (in en). Hindustan Times. 20 May 2020. https://www.hindustantimes.com/india-news/bharat-biotech-ties-up-with-us-varsity-for-covid-vaccine/story-dyJPOzW2G2rXcwsa9XV3tL.html. 
  17. ↑ "ICMR teams up with Bharat Biotech to develop Covid-19 vaccine" (in en). Livemint. 9 May 2020. https://www.livemint.com/news/india/icmr-teams-up-with-bharat-biotech-to-develop-covid-19-vaccine-11589038719666.html. 
  18. ↑ Chakrabarti, Angana (10 May 2020). "India to develop 'fully indigenous' Covid vaccine as ICMR partners with Bharat Biotech". ThePrint. https://theprint.in/health/india-to-develop-fully-indigenous-covid-vaccine-as-icmr-partners-with-bharat-biotech/418180/. 
  19. ↑ "India's First COVID-19 Vaccine Candidate Approved for Human Trials". The New York Times. 29 June 2020. https://www.nytimes.com/reuters/2020/06/29/world/asia/29reuters-health-coronavirus-india-vaccine.html. 
  20. ↑ "Human trial of India coronavirus vaccine announced". BBC News. 30 June 2020. https://www.bbc.com/news/world-asia-india-53230607. 
  21. ↑ "Bharat Biotech's Covid vaccine 1st in India to get approval for human trials" (in en). The Indian Express. 30 June 2020. https://indianexpress.com/article/india/bharat-biotechs-covid-vaccine-1st-in-india-to-get-approval-for-human-trials-6482403/. 
  22. ↑ "Covaxin: India's first COVID19 vaccine candidate from Bharat Biotech to begin human trials; check details". The Financial Express. 30 June 2020. https://www.financialexpress.com/lifestyle/health/covaxin-bharat-biotech-coronavirus-vaccine-india-first-covid19-vaccine-latest-updates/2008500/. 
  23. ↑ "Bharat Biotech COVID-19 vaccine: Testing underway at CDL-Kasauli, volunteer enrolment begins". Moneycontrol. https://www.moneycontrol.com/news/trends/health-trends/bharat-biotech-covid-19-vaccine-testing-underway-at-cdl-kasauli-volunteer-enrolment-begins-5529041.html. 
  24. ↑ "Human clinical trials of potential Covid-19 vaccine 'COVAXIN' started at AIIMS". DD News (Prasar Bharati, Ministry of I & B, Government of India). 25 July 2020. http://ddnews.gov.in/health/human-clinical-trials-potential-covid-19-vaccine-%E2%80%98covaxin%E2%80%99-started-aiims. 
  25. ↑ "Delhi: 30-year-old is first to get dose of trial drug Covaxin" (in en). The Indian Express. 25 July 2020. https://indianexpress.com/article/india/aiims-administers-first-dose-of-bharat-biotechs-potential-covid-vaccine-to-30-yr-old-man-6521778/. 
  26. ↑ "COVID-19 | Office of Technology Management/Tech Transfer | Washington University in St. Louis". https://otm.wustl.edu/category/covid-19/. 
  27. ↑ "Bharat Biotech to make a billion doses of an intranasal adenovirus vaccine" (in en). The Indian Express. 23 September 2020. https://indianexpress.com/article/india/bharat-biotech-to-manufacture-a-billion-doses-of-nasal-spray-covid-19-vaccine-6607305/. 
  28. ↑ "Bharat Biotech Partners With US University For Covid Intranasal Vaccine". NDTV.com. https://www.ndtv.com/india-news/bharat-biotech-partners-with-us-university-for-covid-intranasal-vaccine-2299947. 
  29. ↑ "COVID-19: Covaxin Vaccine Approved For Children Between 2 to 18" (in en-US). 2021-10-12. https://www.thelivemirror.com/covaxin-approved-for-children-between-2-to-18/. 
  30. ↑ Das, Krishna N. (2021-03-01). "Chinese hackers target Indian vaccine makers SII, Bharat Biotech, says security firm" (in en). Reuters. https://www.reuters.com/article/health-coronavirus-india-china-idUSKCN2AT21O. 

External links



Retrieved from "https://handwiki.org/wiki/index.php?title=Company:Bharat_Biotech&oldid=3481301"